The FDA assessed the safety and efficiency of atidarsagene autotemcel based on knowledge from 37 kids who acquired atidarsagene autotemcel in two one-arm, open up-label scientific trials As well as in an expanded access method.[7] Kids who acquired treatment method with atidarsagene autotemcel were being in comparison to untreated young children (p